Biomarker & Intervention Discovery

Chronic Kidney Disease

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

US DALYs2.70MWHO GHE 2021 · all ages
Global DALYs43.51MWHO GHE 2021 · worldwide
US mortality104.2K deaths/yrWHO GHE 2021
Global mortality1.39M deaths/yrWHO GHE 2021 · worldwide
NIH funding$745MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionGFR decline averages 2-5 mL/min/year on standard care (ACE/ARB + blood pressure control); progression to end-stage…
Best-intervention remissionSGLT2 inhibitors (empagliflozin, dapagliflozin) reduce progression to ESRD by 30-35% in CKD trials (EMPA-KIDNEY…
Gap sizeModerate — SGLT2 inhibitors represent a genuine paradigm shift but are dramatically underused
Primary barrierpractice/access
Full remission profile →

Remission & chronicity

Spontaneous remission
GFR decline averages 2-5 mL/min/year on standard care (ACE/ARB + blood pressure control); progression to end-stage renal disease (ESRD) in ~20-30% at 10 years for moderate CKD; reversal essentially impossible once structural fibrosis established
Best-intervention remission
SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce progression to ESRD by 30-35% in CKD trials (EMPA-KIDNEY, DAPA-CKD); finerenone (non-steroidal MRA) adds 15-20% additional protection; combination slows but does not reverse disease
Gap size
Moderate — SGLT2 inhibitors represent a genuine paradigm shift but are dramatically underused
Primary barrier
practice/access
SGLT2 inhibitors have robust evidence for CKD protection regardless of diabetes status (EMPA-KIDNEY 2023) but prescribing rates in non-diabetic CKD remain very low; ACE/ARB as sole strategy (established in 1990s-2000s) still dominant despite the new data
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACE 229AGTR1 249C5 27CFH 3COL4A5 2EDNRA 208NFE2L2 1025NR3C2 213SLC5A2 190TGFB1 62
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SALVIANOLIC ACID B ? unclear Mechanistic
CANDOXATRIL ? unclear Mechanistic
CILAZAPRIL inhibits Mechanistic
TP0556351 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
SILDENAFIL ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RESCINNAMINE ? unclear Mechanistic
SPIRAPRIL ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ARGIPRESSIN ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
DELAPRIL inhibits Mechanistic
ACETYLCHOLINE ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
IMIDAPRIL inhibits Mechanistic
MALATHION inhibits Mechanistic
MOEXIPRIL ? unclear Mechanistic 56.0 nM (IC50)
VORINOSTAT ? unclear Mechanistic
ILEPATRIL inhibits Mechanistic
RXP470.1 inhibits Mechanistic
CGS-27023A ? unclear Mechanistic
NITROPRUSSIDE ? unclear Mechanistic
ENALAPRILAT ANHYDROUS inhibits Mechanistic 1.2 nM (IC50)
TORSEMIDE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
FOSINOPRIL ? unclear Mechanistic
FUROSEMIDE ? unclear Mechanistic
TEMOCAPRIL HYDROCHLORIDE ? unclear Mechanistic
BENAZEPRIL HYDROCHLORIDE inhibits Mechanistic
CARBARIL inhibits Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
QUINAPRIL ? unclear Mechanistic 8.3 nM (IC50)
COMPOUND 1 [PMID: 24900526] inhibits Mechanistic
COMPOUND 20 [PMID: 22153340] inhibits Mechanistic
BUMETANIDE ? unclear Mechanistic
GALLOPAMIL ? unclear Mechanistic
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic
AZD6605 inhibits Mechanistic

Showing top 40 of 229 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CANDESARTAN CILEXETIL inhibits Mechanistic
CHEMBL:CHEMBL586135 ? unclear Mechanistic
VALSARTAN inhibits Mechanistic 4700.0 nM (Ki)
EPROSARTAN MESYLATE inhibits Mechanistic
FIMASARTAN inhibits Mechanistic
ASCORBIC ACID ? unclear Mechanistic
OLMESARTAN MEDOXOMIL inhibits Mechanistic
AZILSARTAN MEDOXOMIL inhibits Mechanistic
THERAPEUTIC ANDROSTANOLONE ? unclear Mechanistic
CHEMBL:CHEMBL347610 ? unclear Mechanistic
CHEMBL:CHEMBL421088 ? unclear Mechanistic
LOSARTAN POTASSIUM inhibits Mechanistic 5.5 nM (IC50)
CHEMBL:CHEMBL1492017 ? unclear Mechanistic
SPARSENTAN inhibits Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL261693 ? unclear Mechanistic
CHEMBL:CHEMBL1972216 ? unclear Mechanistic
EPROSARTAN ? unclear Mechanistic 7.3 nM (IC50)
C-FOS ANTISENSE ? unclear Mechanistic
SARALASIN ACETATE inhibits Mechanistic
IRBESARTAN inhibits Mechanistic 1.1 nM (Ki)
DISULFIRAM ? unclear Mechanistic
SAPRISARTAN ? unclear Mechanistic
H2O2 ? unclear Mechanistic
CHEMBL:CHEMBL591834 ? unclear Mechanistic
CAPTOPRIL ? unclear Mechanistic
ANGIOTENSIN II ? unclear Mechanistic
CHEMBL:CHEMBL400912 ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
IDOXIFENE ? unclear Mechanistic
CHEMBL:CHEMBL528694 ? unclear Mechanistic
IL-6 ? unclear Mechanistic
ANGIOTENSIN II ACETATE activates Mechanistic
LEVODOPA ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
AZILSARTAN KAMEDOXOMIL inhibits Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
CHEMBL:CHEMBL1445650 ? unclear Mechanistic
MUSCLE RELAXANT ? unclear Mechanistic
CL-329167 ? unclear Mechanistic

Showing top 40 of 249 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NOMACOPAN inhibits Mechanistic
CA2+ inhibits Mechanistic
FLUFENAMIC ACID inhibits Mechanistic
ECULIZUMAB inhibits Mechanistic
OCTANOL inhibits Mechanistic
RAVULIZUMAB inhibits Mechanistic
VILOBELIMAB inhibits Mechanistic
ZILUCOPLAN inhibits Mechanistic
CROVALIMAB inhibits Mechanistic
TESIDOLUMAB ~ modulates Mechanistic
CARBENOXOLONE inhibits Mechanistic
OLENDALIZUMAB inhibits Mechanistic
PEXELIZUMAB inhibits Mechanistic
AVACINCAPTAD PEGOL ? unclear Mechanistic
POZELIMAB inhibits Mechanistic
ZILUCOPLAN SODIUM ~ modulates Mechanistic
AVACINCAPTAD PEGOL SODIUM ? unclear Mechanistic
CARPROFEN inhibits Mechanistic 580.0 nM (Kd)
OXAPROZIN inhibits Mechanistic 640.0 nM (Kd)
SULINDAC inhibits Mechanistic 570.0 nM (Kd)
RALOXIFENE inhibits Mechanistic 710.0 nM (Kd)
CHEMBL2204196 inhibits Mechanistic 440.0 nM (IC50)
CHEMBL2203296 inhibits Mechanistic 210.0 nM (IC50)
CHEMBL4756677 inhibits Mechanistic 620.0 nM (IC50)
CHEMBL5594087 inhibits Mechanistic 940.0 nM (Kd)
CHEMBL5594178 inhibits Mechanistic 700.0 nM (Kd)
CEMDISIRAN ? unclear Clinical
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MENINGOCOCCAL GROUP B VACCINE ? unclear Mechanistic
ECULIZUMAB ? unclear Mechanistic
CHEMBL559015 inhibits Mechanistic 44000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ? unclear Mechanistic
OCRIPLASMIN ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NEBENTAN ? unclear Mechanistic
ATRASENTAN ? unclear Mechanistic 0.31 nM (IC50)
TBC-3711 ? unclear Mechanistic
CLAZOSENTAN inhibits Mechanistic
AMBRISENTAN inhibits Mechanistic
MACITENTAN inhibits Mechanistic
SITAXENTAN SODIUM inhibits Mechanistic
DARUSENTAN inhibits Mechanistic
BOSENTAN ANHYDROUS inhibits Mechanistic
ENRASENTAN inhibits Mechanistic 1.1 nM (Ki)
ZIBOTENTAN inhibits Mechanistic
FR139317 ? unclear Mechanistic
AVOSENTAN inhibits Mechanistic
SPARSENTAN inhibits Mechanistic
BQ-123 inhibits Mechanistic 22.0 nM (IC50)
PREDNISONE ? unclear Mechanistic
ATRASENTAN HYDROCHLORIDE inhibits Mechanistic
TEZOSENTAN inhibits Mechanistic 23.0 nM (IC50)
ENDOTHELIN-1 ? unclear Mechanistic
SOVATELTIDE ? unclear Mechanistic
SITAXENTAN inhibits Mechanistic 1.4 nM (IC50)
APROCITENTAN inhibits Mechanistic
BOSENTAN ? unclear Mechanistic 6.5 nM (Ki)
CHEMBL266628 inhibits Mechanistic 5.0 nM (Ki)
CHEMBL170335 inhibits Mechanistic 65000.0 nM (IC50)
CHEMBL12590 inhibits Mechanistic 20.0 nM (Ki)
CHEMBL11528 inhibits Mechanistic 14.0 nM (Ki)
CHEMBL417429 inhibits Mechanistic 415.0 nM (Ki)
CHEMBL12348 inhibits Mechanistic 700.0 nM (Ki)
CHEMBL175228 inhibits Mechanistic 9.3 nM (IC50)
CHEMBL12779 inhibits Mechanistic 105.0 nM (Ki)
CHEMBL12106 inhibits Mechanistic 5.0 nM (Ki)
CHEMBL12233 inhibits Mechanistic 7.0 nM (Ki)
CHEMBL174699 inhibits Mechanistic 25.0 nM (IC50)
CHEMBL11840 inhibits Mechanistic 4.0 nM (Ki)
CHEMBL367033 inhibits Mechanistic 22.0 nM (IC50)
CHEMBL369821 inhibits Mechanistic 450.0 nM (IC50)
CHEMBL12703 inhibits Mechanistic 1.0 nM (Ki)
CHEMBL275523 inhibits Mechanistic 16.0 nM (Ki)
CHEMBL12557 inhibits Mechanistic 22.0 nM (Ki)

Showing top 40 of 208 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL:CHEMBL1537417 ? unclear Mechanistic
SIMVASTATIN ? unclear Mechanistic
CHEMBL:CHEMBL591631 ? unclear Mechanistic
CHEMBL:CHEMBL578929 ? unclear Mechanistic
MIFEPRISTONE ? unclear Mechanistic
CHEMBL:CHEMBL224318 ? unclear Mechanistic
ROSIGLITAZONE MALEATE ? unclear Mechanistic
DICUMAROL ? unclear Mechanistic
2-NITROFLUORENE ? unclear Mechanistic
CHEMBL:CHEMBL530291 ? unclear Mechanistic
PREDNICARBATE ? unclear Mechanistic
5-FLUOROURIDINE ? unclear Mechanistic
BENZO[E]PYRENE ? unclear Mechanistic
DIPHENADIONE ? unclear Mechanistic
RABEPRAZOLE ? unclear Mechanistic
DEXAMETHASONE SODIUM PHOSPHATE ? unclear Mechanistic
2-METHOXY-1,4-NAPHTHOQUINONE ? unclear Mechanistic
DINITRO CRESOL ? unclear Mechanistic
ALDICARB ? unclear Mechanistic
VITAMIN A ? unclear Mechanistic
ANTIMYCIN A ? unclear Mechanistic
MELENGESTROL ACETATE ? unclear Mechanistic
CHEMBL:CHEMBL168075 ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
BROMOCRIPTINE MESYLATE ? unclear Mechanistic
HEXYLRESORCINOL ? unclear Mechanistic
ISOFLUPREDONE ACETATE ? unclear Mechanistic
LITHIUM ? unclear Mechanistic
1-NAPHTHOL ? unclear Mechanistic
BENZO[B]FLUORANTHENE ? unclear Mechanistic
NANAOMYCIN ? unclear Mechanistic
NIFEDIPINE ? unclear Mechanistic
2-AMINOANTHRACENE ? unclear Mechanistic
CHEMBL:CHEMBL426404 ? unclear Mechanistic
METHOTREXATE ? unclear Mechanistic
E1501 ? unclear Mechanistic
CHEMBL:CHEMBL1329443 ? unclear Mechanistic
CHEMBL:CHEMBL531710 ? unclear Mechanistic
METHYLPREDNISOLONE ACETATE ? unclear Mechanistic
AZAMETHIPHOS ? unclear Mechanistic

Showing top 40 of 1025 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
SPIRONOLACTONE inhibits Mechanistic 2.323 nM (Ki)
EPLERENONE inhibits Mechanistic
CORTICOSTERONE activates Mechanistic
DROSPIRENONE inhibits Mechanistic
BENZODROCORTISONE activates Mechanistic
NIMODIPINE inhibits Mechanistic
FLUDROCORTISONE ACETATE activates Mechanistic
VAMOROLONE inhibits Mechanistic
BUDESONIDE activates Mechanistic
DESOXYCORTICOSTERONE activates Mechanistic
DESOXYCORTICOSTERONE ACETATE activates Mechanistic
LY-2623091 ? unclear Mechanistic
ESAXERENONE inhibits Mechanistic
APARARENONE inhibits Mechanistic
AZD-9977 inhibits Mechanistic
FLUDROCORTISONE activates Mechanistic
CANRENONE inhibits Mechanistic
HYDROCORTISONE BUTYRATE activates Mechanistic
CANRENOATE POTASSIUM inhibits Mechanistic
FELODIPINE inhibits Mechanistic
AZD9567 activates Mechanistic
BALCINRENONE ~ modulates Mechanistic
DEXAMETHASONE activates Mechanistic 33.0 nM (IC50)
RU28318 inhibits Mechanistic
XL550 inhibits Mechanistic
ONAPRISTONE inhibits Mechanistic 470.0 nM (IC50)
FLUTICASONE activates Mechanistic
ZK112993 inhibits Mechanistic
PROGESTERONE inhibits Mechanistic 14.0 nM (IC50)
ALDOSTERONE activates Mechanistic
PF-03882845 inhibits Mechanistic
DESOXYCORTICOSTERONE PIVALATE activates Mechanistic
FINERENONE inhibits Mechanistic
LY2623091 inhibits Mechanistic
PREDNISOLONE activates Mechanistic 37.0 nM (Ki)
OCEDURENONE inhibits Mechanistic
MT-3995 ? unclear Mechanistic
CHEMBL134277 inhibits Mechanistic 1900.0 nM (IC50)
CHEMBL415524 inhibits Mechanistic 334.0 nM (IC50)
MEDROXYPROGESTERONE ACETATE inhibits Mechanistic 1197.0 nM (IC50)

Showing top 40 of 213 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TOFOGLIFLOZIN inhibits Mechanistic
SERGLIFLOZIN ETABONATE inhibits Mechanistic
IPRAGLIFLOZIN inhibits Mechanistic
LICOGLIFLOZIN inhibits Mechanistic
HENAGLIFLOZIN inhibits Mechanistic
YM-543 inhibits Mechanistic
GLUFOSFAMIDE ? unclear Mechanistic
DAPAGLIFLOZIN PROPANEDIOL inhibits Mechanistic
IPRAGLIFLOZIN L-PROLINE inhibits Mechanistic
REMOGLIFLOZIN ETABONATE inhibits Mechanistic
ERTUGLIFLOZIN PIDOLATE inhibits Mechanistic
EMPAGLIFLOZIN inhibits Mechanistic
ERTUGLIFLOZIN inhibits Mechanistic
SOTAGLIFLOZIN inhibits Mechanistic
CANAGLIFLOZIN inhibits Mechanistic
BEXAGLIFLOZIN inhibits Mechanistic
TOFOGLIFLOZIN ANHYDROUS ? unclear Mechanistic
DAPAGLIFLOZIN ? unclear Mechanistic 1.1 nM (EC50)
CHEMBL183937 inhibits Mechanistic 4.0 nM (Ki)
CHEMBL187805 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL187163 inhibits Mechanistic 9.0 nM (Ki)
CHEMBL187749 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL184530 inhibits Mechanistic 230.0 nM (Ki)
CHEMBL184027 inhibits Mechanistic 70.0 nM (Ki)
CHEMBL188013 inhibits Mechanistic 40.0 nM (Ki)
CHEMBL361672 inhibits Mechanistic 520.0 nM (Ki)
CHEMBL187056 inhibits Mechanistic 290.0 nM (Ki)
CHEMBL360824 inhibits Mechanistic 1280.0 nM (Ki)
CHEMBL184364 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL359962 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL184183 inhibits Mechanistic 30.0 nM (Ki)
CHEMBL183790 inhibits Mechanistic 150.0 nM (Ki)
CHEMBL365222 inhibits Mechanistic 20.0 nM (Ki)
CHEMBL187686 inhibits Mechanistic 110.0 nM (Ki)
CHEMBL186823 inhibits Mechanistic 30.0 nM (Ki)
CHEMBL187060 inhibits Mechanistic 20.0 nM (Ki)
CHEMBL362365 inhibits Mechanistic 80.0 nM (Ki)
CHEMBL183689 inhibits Mechanistic 70.0 nM (Ki)
CHEMBL371448 inhibits Mechanistic 491.0 nM (IC50)
CHEMBL382302 inhibits Mechanistic 458.0 nM (IC50)

Showing top 40 of 190 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERFERON ALFA-2B ? unclear Mechanistic
PIOGLITAZONE HYDROCHLORIDE ? unclear Mechanistic
SILYMARIN ? unclear Mechanistic
RITUXIMAB ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
PROTEASOME INHIBITOR ? unclear Mechanistic
FRESOLIMUMAB ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
BINTRAFUSP ALFA ~ modulates Mechanistic
NISEVOKITUG ? unclear Mechanistic
LUSPATERCEPT inhibits Mechanistic
TRETINOIN ? unclear Mechanistic
HYDROCORTISONE BUTYRATE ? unclear Mechanistic
VITAMIN E ? unclear Mechanistic
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic
INOSITOL ? unclear Mechanistic
NICOTINE POLACRILEX ? unclear Mechanistic
FENRETINIDE ? unclear Mechanistic
MELATONIN ? unclear Mechanistic
ISOTRETINOIN ? unclear Mechanistic
VACTOSERTIB ? unclear Mechanistic 12.9 nM (IC50)
TRIAMCINOLONE ? unclear Mechanistic
TAMOXIFEN ? unclear Mechanistic
ADRIAMYCIN ? unclear Mechanistic
HEPARAN SULFATE ? unclear Mechanistic
GOSSYPOL ? unclear Mechanistic
TCDD ? unclear Mechanistic
AMIFOSTINE ANHYDROUS ? unclear Mechanistic
RAMIPRIL ? unclear Mechanistic
ANTIOXIDANT ? unclear Mechanistic
SOTATERCEPT ? unclear Mechanistic
ASPIRIN ? unclear Mechanistic
GALUNISERTIB ? unclear Mechanistic
KEYHOLE LIMPET HEMOCYANIN ? unclear Mechanistic
PIRFENIDONE ? unclear Mechanistic
H2O2 ? unclear Mechanistic
THERAPEUTIC ANDROGEN ? unclear Mechanistic
SANDOSTATIN ? unclear Mechanistic
BROXURIDINE ? unclear Mechanistic
DISITERTIDE ? unclear Mechanistic

Showing top 40 of 62 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “Chronic Kidney Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

60 agents shown (approved or with trial evidence) — 59 not found by the gene-target search above.

Soluble Ferric PyrophosphateNOT in gene-target list

· 5 trials · source: ClinicalTrials.gov
NCT01894906 NCT00548249 NCT00548249

Epoetin alfa

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00090753 NCT00307814

Methoxy polyethylene glycol-epoetin beta [Mircera]NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01191983

Mupirocin ointmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00400595

Polysporin TripleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00400595

Egg white protein puddingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06343727

: Ensure PlusNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06343727

High-flux hemodialysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03190629

On line-hemodiafiltrationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03190629

Methoxy Polyethylene Glycol-Epoetin BetaNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00090753

Epoetin betaNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00090753

Darbepoetin alfaNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00090753

ProbioticsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05359094

temperature controlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00438295

intensive individual support in nutrition and exerciseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06040281

Pegylated Interferon Alfa-2aNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02829775

Recombinant Interferon Alfa 2aNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02829775

Assessment guiding surgery and puncture for AVFNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02880761

Curcumin supplementationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04413266

Empagliflozin 10 MGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06642272

Dapagliflozin 10 MGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06642272

JARDIANCE®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06527846

EtelcalcetideNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01788046

walkingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02155127

NanoD4CKDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05165173

MicroD4CKDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05165173

EverolimusNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01239472

Sensipar®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00189501

Diagnostic biomarker studyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04061811

RosuvastatinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01863914

Program ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06410144

Program BNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06410144

NSAIDsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06860711

LP groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05015647

Gastric Emptying Breath TestNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06306963

ZilebesiranNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06272487

RomidepsinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01638533

VericiguatNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07047547

PraliciguatNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07268638

PAL-40 ActiveNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00032435

PAL-40 PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00032435

phytomenadioneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04247087

placebo solutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04247087

estimated glomerular filtration rate and albuminuriaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03458338

CR845NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03281538

calcium acetateNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00211978

Standard Bicarbonate SolutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00548249

Nitrate-rich beetroot juiceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03826147

Nitrate-depleted beetroot juiceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03826147

InformationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01439516

CKD RegistryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01530958

ATSM + Health CoachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01530958

Cholecalciferol - CKDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01222234

Calcitriol - CKDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01222234

Cholecalciferol - non-CKDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01222234

AtorvastatinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01257009

sonographic measurement of inferior vena cava diameterNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03061552

RIBOFLAVINNOT in gene-target list

Approved · 0 trials · source: Open Targets

SEVELAMER HYDROCHLORIDENOT in gene-target list

Approved · 0 trials · source: Open Targets

FOLIC ACIDNOT in gene-target list

Approved · 0 trials · source: Open Targets

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.